During initial stages of pandemic when there was a global shortage for swabs, SLINTEC reverse engineered and supplied 200,000 swabs which saved LKR 80 million of Sri Lankan government expenditure. These swabs were produced by electrostatically depositing the fine fibres on a flexible fine rod. This is attached to the rod with a binder. This is called the flocking technology. The SLINTEC team initially identified the suitable materials required to make these swabs, plus, studying the manufacturing process and available facilities. At present, 3,000 test kits are manufactured daily in Sri Lanka.
Rapid RT-LAMP COVID detection kit
After several months of dedicated and intense work, SLINTEC has successfully demonstrated the use of loop mediated isothermal amplification PCR coupled with reverse transcription (RTLAMP) as a robust method for SARS-CoV-2 detection in clinical specimens. After demonstrating the proof of concept, SLINTEC RT-LAMP assay was validated against the existing RT-qPCR test at Sri Jayewardenepura University (SJP).
With this intervention, Sri Lanka is expected to save nearly Rs. 150 million a month on COVID-19 testing.
Active Pharmaceutical Ingredients (API)
SLINTEC has taken the initiative to establish Sri Lanka’s first program to synthesize active pharmaceutical ingredients (APIs) of high quality and economic value, in an attempt to minimize the cost of importation and to provide good quality medication for the Sri Lankan community.
SLINTEC conducts the API synthesis program in 3 main stages:
- First, APIs are synthesized in small scale in a fully equipped laboratory, where we explore novel, more efficient and cost effective synthesis pathways for the pharmaceuticals.
- The second stage involves the characterization of pharmaceuticals in the molecular recognition laboratory, where molecules are analyzed using Nuclear Magnetic Resonance (NMR) spectroscopy, Gas Chromatography Mass Spectrometry (GCMS) and Liquid Chromatography Mass Spectrometry (LCMS).
- In the third stage, APIs are scaled up to kilogram quantities in a fully equipped Pilot Plant facility located at SLINTEC Technical Incubation Center. The plant is well-equipped and can produce up to 20-30 kg of pharmaceuticals per batch, it is also in the process of obtaining the GMP (Good Manufacturing Practice) certification.
All API programs in SLINTEC are overseen by a team of highly qualified Senior Research Scientists, Post-Doctoral Fellows and Scientists.